Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Breast Cancer ; 24(5): 720-729, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28247220

RESUMO

PURPOSE: To explore quality-of-life (QOL) issues considered important when deciding on treatment for ductal carcinoma in situ (DCIS). METHODS: Breast Cancer Network of Australia members diagnosed with DCIS in the past 5 years (self-identified) participated in an online survey (Sep-Nov 2015). From a list of 74 QOL issues, participants selected all issues they experienced during DCIS diagnosis, treatment or recovery, then the issues they felt important to making a DCIS treatment decision, and completed the Health Literacy Questionnaire (HLQ). Associations between QOL issues and self-reported treatment received were assessed with χ 2 tests. RESULTS: The primary analysis included 38 participants treated with breast-conserving surgery (n = 15), mastectomy (n = 23), and/or radiotherapy (n = 14). Fatigue-related symptoms (82%) and "fear of progression" (50%) were the most frequently-experienced issues. When deciding on DCIS treatment, the most important consideration was "fear of progression" (50%). A higher proportion of mastectomy (compared to non-mastectomy) patients considered "difficultly looking at yourself naked" (p = 0.03). Radiotherapy (compared to non-radiotherapy) patients were more likely to consider "feeling unwell" important (p = 0.006). Results were similar in a sensitivity analysis involving all 101 respondents (i.e., including 63 respondents who reported receiving chemotherapy, endocrine therapy, and/or Herceptin, suggesting that they may have been treated for invasive breast cancer). Health literacy was high across all nine HLQ scales. CONCLUSION: Fear of progression is a key consideration in DCIS treatment decision making for women with high health literacy. QOL treatment considerations differed by treatments received. Women diagnosed with DCIS may benefit from evidence about QOL to inform treatment decision making.


Assuntos
Neoplasias da Mama/psicologia , Carcinoma Intraductal não Infiltrante/psicologia , Tomada de Decisões , Mastectomia/efeitos adversos , Qualidade de Vida/psicologia , Radioterapia/efeitos adversos , Antineoplásicos Imunológicos/uso terapêutico , Austrália , Imagem Corporal/psicologia , Neoplasias da Mama/terapia , Carcinoma Intraductal não Infiltrante/terapia , Terapia Combinada/efeitos adversos , Progressão da Doença , Estética/psicologia , Medo , Feminino , Letramento em Saúde/estatística & dados numéricos , Humanos , Mastectomia/psicologia , Pessoa de Meia-Idade , Radioterapia/psicologia , Autorrelato , Inquéritos e Questionários , Trastuzumab/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA